New England Journal of Medicine publishes study: Cost-Effectiveness of Implantable Cardioverter-Defibrillators
MedSun: Newsletter #1, February 2006

This study utilized the results of eight randomized trials to evaluate the cost-effectiveness of implantable cardioverter-defibrillators (ICD) used prophylactically to improve survival in patients who are at risk for sudden death as a result of a left ventricular systolic dysfunction, but have not had a life- threatening ventricular arrhythmia. In populations in which a significant device-related reduction in mortality was shown, prophylactic implantation of an ICD had a cost-effectiveness ratio below $100,000 per “quality-adjusted life-year (QALY).”

Additional Information:

Cost-Effectiveness of Implantable Cardioverter-Defibrillators
http://content.nejm.org/cgi/content/full/353/14/1471


MedSun Newsletters are available at www.fda.gov/cdrh/medsun